ストックスクリーナーアプリを入手
2.15
5.39%
0.11
前日終値:
$2.04
開ける：
$2
24時間の取引高:
394.13K
Relative Volume:
6.40
時価総額：
$5.95M
収益：
-
当期純損益:
$-14.11M
株価収益率:
-0.2006
EPS:
-10.7181
ネットキャッシュフロー:
$-13.60M
1週間 パフォーマンス:
-17.31%
1か月 パフォーマンス:
+11.98%
6か月 パフォーマンス:
-28.33%
1年 パフォーマンス:
-59.07%
1日の値動き範囲:
$1.92
$2.20
1週間の範囲:
$1.80
$3.11
52週間の値動き範囲:
$1.6701
$14.24
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
名前
Processa Pharmaceuticals Inc
セクター
電話
443-776-3133
住所
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
2.15 | 7.17M | 0 | -14.11M | -13.60M | -10.72 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-25 | 開始されました | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc (PCSA) 最新ニュース
Processa Pharmaceuticals Inc (PCSA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Processa Pharmaceuticals Inc (PCSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PCSA|Processa Pharmaceuticals Inc|Price:2.640|Chg%:+0.050 - TradingKey
PCSA|Processa Pharmaceuticals Inc|Price:2.605|Chg%:+0.005 - TradingKey
Processa Pharma Market Sentiment - Benzinga España
Processa Pharmaceuticals Inc (PCSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Processa Pharmaceuticals Inc (PCSA) Income Statement - TradingKey
Processa Pharmaceuticals Inc (PCSA) Balance Sheet - TradingKey
PCSA|Processa Pharmaceuticals Inc|Price:2.600|Chg%:-0.270 - TradingKey
Processa Pharmaceuticals Inc (PCSA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Processa Pharmaceuticals Q4 2025 Earnings: EPS Miss Drives Stock Surge – Investor Focus Shifts to Pipeline - dars.gov.et
Processa Pharma (PCSA) Stock Analysis Report | Financials & Insights - Benzinga España
Insider Buying: Russell Skibsted Acquires Additional Shares of P - GuruFocus
Processa Pharmaceuticals CEO George Ng acquires $5,900 in stock - Investing.com
Processa Pharmaceuticals CEO George Ng acquires $5,900 in stock By Investing.com - Investing.com South Africa
Form 4 Processa Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
Insider purchase: Processa (NASDAQ: PCSA) CAO adds 2,436 shares in open-market buy - Stock Titan
Processa (PCSA) strategy chief adds 2,106 shares in insider buy - Stock Titan
Processa Pharmaceuticals (PCSA) CEO adds 3,057 shares in open-market buy - Stock Titan
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Ng George K - Moomoo
CFO of Processa (NASDAQ: PCSA) adds 3,277 shares in open-market buy - Stock Titan
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer SKIBSTED RUSSELL - Moomoo
Processa Pharmaceuticals (PCSA) director buys 2,531 shares in open market - Stock Titan
Processa Pharmaceuticals, Inc. Financial Disclosures & SEC Filings - TradingView
Form 4 Processa Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Processa (NASDAQ: PCSA) director Yorke vests 203-share restricted stock award - Stock Titan
[Form 4] Processa Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Processa Pharmaceuticals (PCSA) director receives 203 shares from vesting - Stock Titan
Processa Pharmaceuticals (PCSA) director gets 203 shares from service award - Stock Titan
PCSA Q4 2025 Earnings: Wider-Than-Expected EPS Loss Amid Pipeline DevelopmentAnnual Report - dars.gov.et
PCSA Q4 2025 Earnings: Wider-than-Expected Loss Highlights Clinical Stage ChallengesEarnings Turnaround - dars.gov.et
Enterprise value to EBIT forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Price to sales forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Price to book forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Price to earnings forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Enterprise value to revenue forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Processa Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:PCSA) - TradingView
PCSA | Processa Pharmaceuticals, Inc. Common Executive Compensation - Quiver Quantitative
Shareholders to vote on Processa (NASDAQ: PCSA) equity plan and pay - Stock Titan
Processa Pharmaceuticals | DEF 14A: Definitive information statements - Moomoo
Processa Pharmaceuticals Inc (PCSA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Processa Pharmaceuticals Inc (PCSA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Processa Pharmaceuticals Inc - TradingKey
Processa Pharmaceuticals Inc (PCSA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Processa Pharmaceuticals Inc (PCSA) Institutional Confidence - TradingKey
Processa Pharmaceuticals CFO Russell Skibsted buys $5,891 in stock By Investing.com - Investing.com UK
Processa Pharmaceuticals chief business officer Lin buys $4,064 stock By Investing.com - Investing.com India
Processa Pharmaceuticals CEO George Ng buys $5,472 in stock By Investing.com - Investing.com Australia
Processa Pharmaceuticals CFO Russell Skibsted buys $5,891 in stock - Investing.com
Processa Pharmaceuticals chief business officer Lin buys $4,064 stock - Investing.com UK
Processa Pharmaceuticals CEO George Ng buys $5,472 in stock - Investing.com UK
Processa Pharmaceuticals Inc (PCSA) 財務データ
収益
当期純利益
現金流量
EPS
Processa Pharmaceuticals Inc (PCSA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lin Patrick | Chief Business - Strategy Off |
Jun 30 '26 |
Buy |
1.93 |
2,106 |
4,065 |
13,113 |
| Ng George K | Chief Executive Officer |
Jul 01 '26 |
Buy |
1.93 |
3,057 |
5,900 |
15,492 |
| SKIBSTED RUSSELL | Chief Financial Officer |
Jun 30 '26 |
Buy |
1.93 |
3,277 |
6,325 |
16,689 |
| Young David | Pres. Research & Development |
Jun 30 '26 |
Buy |
1.93 |
2,531 |
4,885 |
21,729 |
| Young David | Pres. Research & Development |
Jun 15 '26 |
Buy |
2.22 |
2,067 |
4,589 |
19,198 |
| SKIBSTED RUSSELL | Chief Financial Officer |
Jun 15 '26 |
Buy |
2.22 |
2,654 |
5,892 |
13,412 |
| Ng George K | Chief Executive Officer |
Jun 15 '26 |
Buy |
2.22 |
2,465 |
5,472 |
12,435 |
| Lin Patrick | Chief Business - Strategy Off |
Jun 15 '26 |
Buy |
2.22 |
1,831 |
4,065 |
11,007 |
| Guy Wendy | Chief Administrative Officer |
Jun 15 '26 |
Buy |
2.22 |
2,118 |
4,702 |
11,958 |
| Young David | Pres. Research & Development |
May 29 '26 |
Buy |
2.57 |
1,786 |
4,590 |
17,131 |
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):